Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide 2.4 mg s.c. weekly in overweight or obese adults with or without type 2 diabetes
CTR20202040Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in obesity, Overweight, type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Oct 2020; status: completed.
02
Drugs
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20202040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202040.